Queen Elizabeth Hospital Birmingham Selects Raystation
News Sep 17, 2016
Queen Elizabeth Hospital Birmingham (QEHB) has selected the RayStation® treatment planning system following an extensive evaluation of market-leading systems. The agreement includes both clinical and research licenses, and the installation will include adaptive planning, multi-criteria optimization, automated breast planning, scripting and radiobiology. QEHB is part of University Hospitals Birmingham NHS Foundation Trust, which is one of the largest regional centers for non-surgical cancer treatment in the UK.
The center offers a high degree of sub-specialization by tumor site and treats patients from the whole of the British Isles and from overseas. The radiation therapy department at QEHB has some of the most advanced facilities available in the UK; its equipment portfolio includes six linacs, two TomoTherapy systems and a CyberKnife system. RayStation has the flexibility and compatibility needed to meet the future planning needs of such a leading-edge center with a broad range of treatment machines.
Jason Cashmore, head of treatment planning at QEHB, says: “A thorough evaluation made it clear that RayStation was the best solution to meet our needs now and in the long term. Its processing speed, coupled with advanced automation and scripting capabilities, will enable us to optimize adaptive planning workflows and save significant clinician time.”
Johan Löf, CEO of RaySearch, says: “We look forward to working with Queen Elizabeth Hospital Birmingham and to providing a unified platform for all its radiation treatment planning. The team at QEHB has a clear direction toward automation and adaptive planning and also operates diverse and advanced treatment equipment. This is exactly the kind of environment in which RayStation excels.”
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers say they have identified that target - an enzyme called PPT1 - opening up a new pathway for potential cancer treatments.READ MORE